What does targeted radioisotope therapy treat?

A carrier molecule travels through the bloodstream and attaches to a matching feature on cancer cells. The attached radioisotope releases radiation close to those cells, which can damage them while limiting exposure to tissues without the target. It is a specialised treatment rather than a single medicine for every cancer.

Doctors may consider it for some neuroendocrine tumours, prostate cancer, or neuroblastoma when tests show that the tumour can take up the relevant medicine. The exact product depends on the target, the tumour location, previous treatment, kidney function, blood counts, and overall health.

Bring a list of previous cancer treatments, medicines, allergies, and any kidney problems. Ask which scan or laboratory test confirms the target and whether the treatment is intended to shrink disease, control it, or ease symptoms. Your team may explain hydration, other medicines, radiation-safety precautions, and the timing of follow-up blood tests.

The radioactive material may be delivered through a vein or another planned route, depending on the therapy. Treatment can involve more than one visit, and monitoring helps the team adjust care if blood counts or kidney measurements change.

Contact your oncology team promptly for fever, unusual bleeding, repeated vomiting, marked weakness, reduced urine, or new worsening pain after treatment. Seek urgent help for trouble breathing, fainting, confusion, or swelling of the face or throat. The instructions provided by your treatment centre take priority because precautions vary by medicine.

Which target does my tumour carry, and how was it confirmed? What benefits are realistic for my situation? What effects should I watch for at home, and who should I call outside clinic hours? Will I need changes to medicines, eating, drinking, travel, or close contact with others?